In-vitro activity of meropenem against Neisseria gonorrhoeae, Haemophilus influenzae and H. ducreyi from Canada and Kenya.
Meropenem, a new parenteral carbapenem demonstrated increased activity as compared to imipenem against 336 strains of Neisseria gonorrhoeae, 119 strains of Haemophilus influenzae, and 110 strains of H. ducreyi. Neither carbapenem was affected by the beta-lactamase activity of the organisms tested. Ceftriaxone and ciprofloxacin demonstrated activity superior to that of both carbapenems while the activity of ceftazidime was similar to that of meropenem.
Slaney
L
L
Department of Medical Microbiology, University of Manitoba, Winnipeg, Canada.
Chubb
H
H
Mohammed
Z
Z
Ronald
A
A
D000900:Anti-Bacterial Agents / Q000494:pharmacology; D002170:Canada; D015780:Carbapenems / Q000494:pharmacology*; D006069:Gonorrhea / Q000382:microbiology; D006192:Haemophilus Infections / Q000382:microbiology; D006191:Haemophilus ducreyi / Q000187:drug effects*; D006193:Haemophilus influenzae / Q000187:drug effects*; D006801:Humans; D007630:Kenya; D000077731:Meropenem; D008826:Microbial Sensitivity Tests; D009344:Neisseria gonorrhoeae / Q000187:drug effects*; D013845:Thienamycins / Q000494:pharmacology*
D000900:Anti-Bacterial Agents; D015780:Carbapenems; D013845:Thienamycins; D000077731:Meropenem